In the present study, we focused on a novel synthetic small molecular agent, NVP-BEZ235, that was designed to treat RCC by simultaneously inhibiting the activity of PI3K and mTORC1 in PI3K/Akt/mTOR pathway. This evidence concerns the gene AKT1 and renal cell carcinoma.